Asia Pacific Respiratory Inhalers Market

The Asia Pacific respiratory inhalers market is expected to grow from US$ 6,397.09 million in 2022 to US$ 9,297.48 million by 2028. It is estimated to register a CAGR of 6.4% from 2022 to 2028.

Increasing Product Development Activities to Fuel Asia Pacific Respiratory Inhalers Market Growth

With new medical knowledge and effective medicines, treatment with a wide range of asthma inhalers continues to advance. Rising use of ventilator combination therapies and increasing investments by major players in developing sophisticated ventilator inhalers are boosting the demand for respiratory inhalers. In addition to the numerous advantages of the device, such as portability, convenience, and effectiveness, the growing number of product approvals and developments is expected to strengthen the demand for respiratory inhalers in the coming years. A few of the major developments and approvals have taken place in recent years. For instance, in November 2022, AstraZeneca partnered with Avillion to develop PT027, an asthma rescue inhaler. PT027 is a pressurized metered-dose inhaler that delivers a fixed dose of two combined asthma medications: albuterol—a short-acting beta2-agonist and budesonide, an anti-inflammatory inhaled corticosteroid. Similarly, in December 2020, OMRON launched WheezeScan, the world’s first wheeze detection device to help children with asthma, which is a crucial breakthrough in the field of pediatric asthma management. WheezeScan helps parents of young children detect wheezing—a clear indicator of an upcoming asthma attack-—and act accordingly. Thus, such increasing advancements by various market players and product approvals are likely to catalyze the growth of the Asia Pacific respiratory inhalers market during the forecast period.

Asia Pacific Respiratory Inhalers Market Overview

The market for Asia Pacific includes Japan, China, India, South Korea, Australia, and the Rest of APAC. Asia Pacific is expected to be the fastest-growing region, with China accounting for the major market share. China is one of the fastest developing economies in Asia Pacific, with a GDP of US$ 18 trillion, which accounts for 18% of the global economy. Healthcare expenditure in the country accounts for 7.1% of the GDP. As per China Macro Economy Journal 2021, ~264 million people aged 60 years and above accounted for 18.7% of the total population of the country. The presence of a large geriatric population has increased the respiratory disease burden as the elderly population is prone to various health conditions. As per the Frontier Media Public Health report published in June 2022, the most recent Chinese national survey of COPD showed that China accounted for almost 25% of all COPD cases globally. Compared to the survey results from 10 years ago, the prevalence of COPD has increased by 67% in the 40 and older group and has reached epidemic proportions. Moreover, asthma is a major public health challenge in the country, affecting millions of people. According to the National Library of Medicine, the prevalence of asthma in 2019 was 4.2%, representing 45.7 million people in the country. This has further increased the demand for respiratory inhalers. Moreover, the COVID-19 outbreak created a demand for respiratory inhalers. The geographical expansion of various companies from other countries is also likely to support the market growth.

Asia Pacific Respiratory Inhalers Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Respiratory Inhalers Market Segmentation 

The Asia Pacific respiratory inhalers market is segmented based on product type, technology, disease indication, and country.

Based on product type, the Asia Pacific respiratory inhalers market is segmented into nebulizers, metered dose inhalers (MDI), and dry powder inhalers. The dry powder inhalers segment held the largest share of the Asia Pacific respiratory inhalers market in 2022.

Based on technology, the Asia Pacific respiratory inhalers market is bifurcated into manually operated inhalers and digitally operated inhalers. The manually operated inhalers segment held a larger share of the Asia Pacific respiratory inhalers market in 2022.  

Based on disease indication, the Asia Pacific respiratory inhalers market is segmented into asthma, COPD, pulmonary arterial hypertension, and others. The asthma segment held the largest share of the Asia Pacific respiratory inhalers market in 2022.   

Based on country, the Asia Pacific respiratory inhalers market has been categorized into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. China dominated the Asia Pacific respiratory inhalers market in 2022. 

AstraZeneca Plc; Beximco Pharmaceuticals Ltd.; Boehringer Ingelheim International GmbH; Cipla Ltd; GSK Plc; Koninklijke Philips NV; OMRON Corp; OPKO Health, Inc; PARI Respiratory Equipment, Inc.; and Teva Pharmaceutical Industries Ltd are the leading companies operating in the Asia Pacific respiratory inhalers market. 

Asia Pacific Respiratory Inhalers Market Strategic Insights

Asia Pacific Respiratory Inhalers Market Segmentation Analysis

Asia Pacific Respiratory Inhalers Market Report Highlights

Asia Pacific Respiratory Inhalers Report Scope

Asia Pacific Respiratory Inhalers Market Country and Regional Insights